Q1 Earnings Forecast for PTCT Issued By William Blair

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Equities researchers at William Blair issued their Q1 2026 earnings estimates for shares of PTC Therapeutics in a note issued to investors on Friday, February 28th. William Blair analyst S. Corwin expects that the biopharmaceutical company will post earnings per share of ($0.57) for the quarter. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.37) EPS and Q4 2026 earnings at ($0.13) EPS.

Other research analysts have also recently issued research reports about the stock. UBS Group upped their price target on shares of PTC Therapeutics from $47.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Barclays raised their price objective on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 3rd. StockNews.com cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Citigroup lifted their price target on PTC Therapeutics from $32.00 to $45.00 and gave the company a “sell” rating in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald raised their price objective on shares of PTC Therapeutics from $76.00 to $113.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $62.08.

PTC Therapeutics Stock Performance

PTCT opened at $52.87 on Monday. PTC Therapeutics has a twelve month low of $24.00 and a twelve month high of $55.60. The firm has a market cap of $4.08 billion, a PE ratio of -8.90 and a beta of 0.62. The firm’s fifty day moving average is $47.31 and its two-hundred day moving average is $42.46.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, CEO Matthew B. Klein sold 8,279 shares of PTC Therapeutics stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $45.16, for a total transaction of $373,879.64. Following the transaction, the chief executive officer now directly owns 217,528 shares of the company’s stock, valued at $9,823,564.48. The trade was a 3.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lee Scott Golden sold 795 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total transaction of $39,829.50. Following the completion of the sale, the executive vice president now owns 77,856 shares of the company’s stock, valued at approximately $3,900,585.60. This represents a 1.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,640 shares of company stock valued at $1,012,288 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTCT. Vontobel Holding Ltd. bought a new position in shares of PTC Therapeutics during the 4th quarter worth approximately $521,000. Charles Schwab Investment Management Inc. lifted its holdings in PTC Therapeutics by 7.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock worth $26,220,000 after acquiring an additional 47,902 shares during the period. Two Sigma Advisers LP boosted its position in PTC Therapeutics by 10.3% in the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company’s stock worth $15,947,000 after purchasing an additional 40,300 shares during the last quarter. Intech Investment Management LLC bought a new position in PTC Therapeutics in the 3rd quarter valued at $698,000. Finally, Quest Partners LLC increased its position in shares of PTC Therapeutics by 433.9% during the 3rd quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 18,171 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.